Table 1.
Patient and tumor characteristics (n = 478)
| Variables | EGFR-mutant (n = 162) |
Wild-type (n = 316) |
P |
|---|---|---|---|
| Age | 0.010 | ||
| < 65 y | 52 (32.1) | 67 (21.2) | |
| ≥ 65 y | 110 (67.9) | 249 (78.8) | |
| Sex | < 0.001 | ||
| Males | 51 (31.5) | 237 (75.0) | |
| Females | 111 (68.5) | 79 (25.0) | |
| Brinkman index | < 0.001 | ||
| < 400 | 122 (75.3) | 85 (26.9) | |
| ≥ 400 | 40 (24.7) | 231 (73.1) | |
| Clinical stage | < 0.001 | ||
| 0 or I | 154 (95.1) | 246 (77.8) | |
| II or III | 8 (4.9) | 70 (22.2) | |
| Histologic type | |||
| Adenocarcinoma (n = 348) | 161 (99.4) | 187 (59.2) | |
| Squamous cell carcinoma (n = 96) | 0 (0) | 96 (30.4) | |
| Other types (n = 34)a | 1 (0.6) | 33 (10.4) |
EGFR, epidermal growth factor receptor.
Data are presented as numbers (%).
a
Eleven neuroendocrine carcinomas, eight adenosquamous cell carcinomas, five pleomorphic carcinomas, three large cell carcinomas, three carcinosarcomas, three carcinoids, and one mucoepidermoid carcinoma.